NCT06891118Completed
Stellate Ganglion Blockade for Refractory Chronic Migraine
Ultrasound-Guided Stellate Ganglion Block for Refractory Chronic Migraine: A Prospective Evaluation
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Stellate Ganglion Block (SGB) is an interventional anesthetic technique used to treat pain conditions affecting the head, face, neck, and upper extremities by temporarily blocking sympathetic nerve output. Ultrasound guidance improves anatomical visualization and facilitates accurate needle placement. Emerging evidence suggests that repeated ultrasound-guided SGB may be associated with reductions in headache intensity and frequency in patients with migraine and with improvement in migraine-related disability. However, limited data exist regarding its use in highly treatment-resistant chronic migraine, particularly in patients who have not responded adequately to preventive pharmacological therapies and prior interventional treatments. The primary objective of this study is to evaluate 6-month clinical outcomes following ultrasound-guided SGB in patients with treatment-resistant chronic migraine. Secondary objectives include assessing changes in pain intensity, migraine-related disability, analgesic use, patient-reported global improvement, and treatment tolerability.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 6 Mar 2025
- Start date
- 6 Mar 2024
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Ankara City Hospital Bilkent
- Diseases
- Migraine
- NCT number
- NCT06891118
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 6 Mar 2024 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Migraine-related interventional treatment, botulinum toxin A treatment, or nonpharmacological headache treatment (e.g., acupuncture, ozone therapy, or cognitive behavioral therapy) within the previous 3 months.
Other illness
- History of a primary headache disorder other than migraine.
- Infection at the planned injection site.
- Known allergy to local anesthetic agents.
- History of malignancy or cranial/cervical surgery.
- Bleeding or coagulation disorder, or current oral anticoagulant therapy.
- Comorbid conditions that could contribute to headache, such as uncontrolled hypertension or intracranial lesions.
- Conditions that could impair adherence to the treatment or follow-up protocol, such as significant psychiatric disease or dementia.
Other
- Pregnancy or suspected pregnancy.
- Unwillingness to undergo the planned interventional treatment or to continue the study protocol.
Who the study is looking for
- Adults aged 18-65 years.
- Diagnosis of chronic migraine according to ICHD-3 criteria.
- Insufficient clinical response to prior preventive migraine treatment.
- Prior interventional headache treatment performed at least 3 months before enrollment, with insufficient clinical benefit.
- Willingness and ability to participate in the study, comply with follow-up, and undergo the planned interventional treatment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Health Sciences University, Ankara Bilkent City Hospital Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.